ArgentinaDr. María Lorena Di GianoRESEARCH TEAMBelizeCaleb Orozco, United Belize Advocacy MovementCambodiaPen MonyCameroonWendi Losha Bernadette and Dr. Oliver Birnso VerbeChinaAnonymous research and writing teamDominican RepublicEugene Schiff and Felix ReyesIndiaAbraham KK, Celina D’Costa, Bobby Jayanta, Murali Shunmugam,Dr. Venkatesan Chakrapani, Indian Network for People living with HIV (INP+)KenyaElizabeth Owiti, Healthpartners;James Kamau, Kenya Treatment <strong>Access</strong> Movement-KETAMMalawiLot Nyirenda and Grace BongololoMoroccoOthman MelloukNigeriaOlayide Akanni, Journalists Against <strong>AIDS</strong> Nigeria;Bede Eziefule, Center for <strong>the</strong> Right to HealthPakistanProf. M. Ismail, Pakistan National <strong>AIDS</strong> ConsortiumPhilippinesNenet L. Ortega, Noel Quinto, and Eddy RazonRussiaShona Schonning, Eurasian Harm Reduction Network (EHRN);Sergey Kovalevsky, ITPC; Anastasia Agafonova, ITPC; Vladimir Osin, ITPC;Smiljka de Lussigny, European <strong>AIDS</strong> Treatment Group (EATG)i
UgandaRosette Mutambi, Aaron Muhinda, Beatrice Were, Prima Kazoora, andRichard HasuniraZambiaPaul Kasonkomona and Felix MwanzaZimbabweMatilda Moyo, Caroline Mubaira, and Martha TholanahAnalysis of drug access issuesBrook Baker and Asia RussellProject coordinatorsChris Collins, Gregg Gonsalves, and Maureen BaehrEditingJeff Hoover and Bob HuffResearch, editing, and administrative assistanceErika BaehrMedia coordinationKay MarshallDesignLei ChouThe report team would like to thank <strong>the</strong> following people for <strong>the</strong>ir assistance:David Barr, Roxana Bonnell, Mark Harrington, Irene Keizer, Susie Lim,Javid Syed, Mitchell Warren, Sonya Watson, Yuko Woodford,<strong>AIDS</strong> Vaccine Advocacy Coalition (AVAC), The HIV Collaborative Fund,Health GAP, The Tides Center, and Treatment Action Group (TAG).This report was made possible by support from <strong>the</strong> Open Society Institute,Aids Fonds, UK Department for International Development (DFID),<strong>the</strong> HIV Collaborative Fund, and <strong>the</strong> John M. Lloyd Foundation.The <strong>Missing</strong> <strong>the</strong> <strong>Target</strong> series is part of <strong>the</strong>Treatment Monitoring and Advocacy Project (TMAP).TMAP is a project of The Tides Center, San Francisco.Contact informationProject coordination:Chris Collins, ChrisCSF@aol.comGregg Gonsalves, gregg.gonsalves@gmail.comInternational Treatment Preparedness Coalition (ITPC): SG-ITPC@yahoogroups.comii
- Page 1 and 2: Missing the Target #5:Improving AID
- Page 8 and 9: Executive SummaryAt the G8 meeting
- Page 12: • UN agencies should provide incr
- Page 16 and 17: Price should not be a barrier when
- Page 18 and 19: The Global Fund and UNITAID: The Fu
- Page 20 and 21: The real cost of free treatmentBy a
- Page 22 and 23: Remaining work for asuccessful prog
- Page 24 and 25: DOMINICAN REPUBLICto access rapid t
- Page 26 and 27: DOMINICAN REPUBLICIn Santo Domingo
- Page 28 and 29: ZIMBABWEtreatment, representing 35
- Page 30 and 31: ZIMBABWEAccording to the Medicines
- Page 32 and 33: ZIMBABWEZimbabwe’s application fo
- Page 34 and 35: ZIMBABWENational government• Addr
- Page 36 and 37: RUSSIAMigrantsRussia, with the seco
- Page 38 and 39: a person with HIV will die very qui
- Page 40 and 41: FamiliesIn Kenya, families are the
- Page 42 and 43: INDIA2. Provide pediatric formulati
- Page 44 and 45: Linking nutrition and treatmentBy W
- Page 46 and 47: Most people living with advanced HI
- Page 48 and 49: only available in the capital, Yaou
- Page 50 and 51: ZAMBIAFindings in particular provin
- Page 52 and 53: The DACA for Chadiza District was a
- Page 54 and 55:
Many health care workers are inadeq
- Page 56 and 57:
DRUG REGISTRATION BARRIERS & LOGJAM
- Page 58 and 59:
Country ATV RLPV/rLPV/r(HS)TDFArgen
- Page 60 and 61:
development and registration. Likew
- Page 62 and 63:
Capacity issues and delays in the W
- Page 64 and 65:
Lack of post-approval quality assur
- Page 66 and 67:
ARV PROCUREMENT, REGISTRATION,AND S
- Page 68 and 69:
ARGENTINAParallel importingRelating
- Page 70 and 71:
ARGENTINAAccess to ARVsNo difficult
- Page 72 and 73:
Viral load tests are available, but
- Page 74 and 75:
Cambodiaby Mony PenOnly pharmacists
- Page 76 and 77:
ChinaBy anonymous Missing the Targe
- Page 78 and 79:
CHINAThe current process for regist
- Page 80 and 81:
Dominican RepublicBy Eugene Schiff
- Page 82 and 83:
IndiaBy Abraham KK, Celina D’Cost
- Page 84 and 85:
MalawiBy Lot Nyirenda and Grace Bon
- Page 86 and 87:
MALAWIStock-outsAccording to an ext
- Page 88 and 89:
MoroccoBy Othman MelloukMorocco has
- Page 90 and 91:
Determine the patent status of all
- Page 92 and 93:
MOROCCOThe shortage occurred becaus
- Page 94 and 95:
As of November 2007, the unit cost
- Page 96 and 97:
NIGERIADiagnostic testsDiagnostic t
- Page 98 and 99:
The government’s initial inabilit
- Page 100 and 101:
Increase training and capacity buil
- Page 102 and 103:
treatment practice. The Minster ann
- Page 104 and 105:
Ugandaby Richard Hasunira, Prima Ka
- Page 106 and 107:
UGANDAExtracts from the MoH’s rep
- Page 108 and 109:
ZAMBIAIn gathering this information
- Page 110 and 111:
However, since manufacturing prices
- Page 112 and 113:
105SHORT SUMMARY
- Page 114:
PAKISTANAccess for marginalized gro